What is the 13F Pro Quality Score for RMD?

13F Pro ranks RESMED INC (RMD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RMD's current score at https://13fpro.ai/company/RMD (free sign-up required for the full ranking).

Where does 13F Pro source RMD data?

All RESMED INC fundamentals and ownership data come directly from SEC EDGAR. RESMED INC files with the SEC under CIK 943819. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RMD in?

RESMED INC (RMD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives RMD's revenue?

Per RESMED INC's latest 10-K filed with the SEC on 2026-08-13, the biggest revenue drivers are: Sleep and Breathing Health ($2.87B). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/RMD.

What are RMD's largest expenses?

RESMED INC's latest 10-K reports these as the largest expense items: Cost of sales (including depreciation and amortization); Selling, general and administrative ($1.16B). Sourced directly from SEC EDGAR filing text for FY2026 (year ended June 30, 2026).

How often is RMD research updated on 13F Pro?

RMD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

RESMED INC(RMD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 943819 RMD stock profile & AI dashboard →

13F Pro Quality Score

74.3/100

Rank #113 of 2,961 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

59.1/100

Profitability

85.4/100

Balance Sheet

95.5/100

Earnings Quality

65.7/100

Free Cash Flow

83.2/100

Institutional Flow

67.8/100

Revenue Scale

79.7/100

Dilution Risk

41.4/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why RMD Scores 74/100

exact factor attribution · 2026-09-11

RMD's composite is driven by profitability and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Profitability

+5.3 pts

85th pct

Free cash flow

+5.0 pts

83th pct

Capital efficiency

+4.5 pts

96th pct

Scale

+4.5 pts

80th pct

Revenue growth

+1.8 pts

59th pct

Earnings quality

+1.6 pts

66th pct

Earnings growth

+1.2 pts

74th pct

Institutional flow

+0.9 pts

68th pct

Shareholder dilution

-0.4 pts

41th pct

Latest change (2026-08-13): 80 → 76 · ↓ Revenue growth 65→51; ↓ Earnings growth 73→59

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

RMD Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for RESMED INC (RMD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RMD at 74.3/100 on a 32-signal composite quality model, placing it at rank #113 of 2,961 stocks — the top 5% of the AI-ranked universe. RMD scores in the top quartile across balance sheet strength (95.5), profitability (85.4), free cash flow (83.2). Shareholder dilution risk is elevated at 41.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), RESMED INC reports quarterly revenue of $1.5B, net income of $383.4M, an operating margin of 30.7%. Top institutional holders of RMD by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. RMD trades on the NYSE exchange and files with the SEC under CIK 943819. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RESMED INC directly from SEC EDGAR. RESMED INC's 13F Pro composite quality score has ranged between 61 and 84 since 2021, currently 74.3 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about RESMED INC

Quirks, history, and lore behind RMD — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · mid-to-large cap · listed on the NYSE · headquartered in San Diego, California with major operations in Australia.
2
The Numbers
Annual revenue in the range of $4 billion, serving patients in over 140 countries — a surprisingly global footprint for a company most people have never heard of.
3
The History
Founded in Australia in the 1980s by a physician-entrepreneur who believed a common sleep disorder was being dangerously undertreated, it later dual-listed and planted its commercial roots in San Diego.
4
The Secret
It doesn't just sell hardware — a huge chunk of its business is cloud-connected software that remotely monitors patients every night while they sleep, generating sticky subscription-style revenue.
5
The Lore
When a rival's products were recalled over safety concerns in the early 2020s, this company's stock surged dramatically as millions of patients needed an alternative — a textbook case of one competitor's nightmare being another's windfall.
6
The Giveaway
It is the world's leading maker of CPAP machines and masks for sleep apnea — if you or someone you love wears a breathing mask to bed, there's a good chance this company made it.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving RMD's Business? Latest 10-K Breakdown

AI-extracted from RESMED INC's 10-K filed 2026-08-13 — FY2026 (year ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

ResMed reported fiscal year 2026 revenue of $3.26B, driven by Sleep and Breathing Health segment growth and software expansion, while acquiring Noctrix and planning to divest MatrixCare.

Biggest Revenue Drivers

Sleep and Breathing Health$2.87B

Core business segment providing CPAP, bilevel, ventilation devices, masks and connected digital health solutions for OSA and respiratory disorders.

Biggest Revenue Drivers

Total revenue: $3.26B

Sleep and Breathing Health$2.87B

Core business segment providing CPAP, bilevel, ventilation devices, masks and connected digital health solutions for OSA and respiratory disorders.

Largest Expense Items

Cost of sales (including depreciation and amortization)

Manufacturing, procurement and delivery of devices, masks and software solutions.

Selling, general and administrative$1.16B

Sales, marketing, distribution and administrative support across global operations.

Margins: The filing discusses gross margin pressures from inflation, supply chain disruptions, and competitive bidding programs affecting reimbursement, while noting ongoing investments in R&D and digital health capabilities to support long-term growth.

Watch Items from the Filing

VirtuOx (acquired 2025) is under a five-year Corporate Integrity Agreement (CIA) through 2027 following a $3M settlement; any CIA breach could result in exclusion from federal healthcare programs.
Noctrix device (acquired June 2026) lacks national Medicare coverage determination; coverage decisions made case-by-case by Medicare contractors, creating reimbursement uncertainty.
MatrixCare business (representing ~12% of annual revenue) is being divested for $490M; transaction expected to close in Q1 FY2027, reflecting portfolio optimization toward core sleep and breathing health.
Global tariffs and supply chain constraints remain dynamic risks; company sources components from multiple countries and manufactures in Singapore, Australia, Malaysia, China, and U.S., with potential exposure to new or increased tariffs.
Competitive reintroduction of Philips flow generators (historically under consent decree) could reduce demand; temporary market window from Philips recall may diminish as Philips returns to market.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-K on SEC EDGAR →Share on X

Revenue

Q2 2026

$1.5B

Net Income

Q2 2026

$383.4M

Free Cash Flow

Q2 2026

$403.5M

Operating Margin

Q2 2026

30.7%

ROIC

Q2 2026

24.8%

D/E Ratio

Q2 2026

0.10

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+9.9% YoY

$5.65BFY 2026

FY23 $4.22BFY24 $4.69BFY25 $5.15BFY26 $5.65B

Net Income

+8.8% YoY

$1.52BFY 2026

FY23 $897.6MFY24 $1.02BFY25 $1.40BFY26 $1.52B

Operating Income

+11.9% YoY

$1.89BFY 2026

FY23 $1.13BFY24 $1.32BFY25 $1.69BFY26 $1.89B

EPS (Diluted)

+9.7% YoY

$10.43FY 2026

FY23 $6.09FY24 $6.92FY25 $9.51FY26 $10.43

Total Assets

+9.7% YoY

$8.97BFY 2026

FY23 $6.75BFY24 $6.87BFY25 $8.17BFY26 $8.97B

Total Debt

-1.3% YoY

$659.4MFY 2026

FY23 $1.44BFY24 $707.2MFY25 $668.3MFY26 $659.4M

Op. Cash Flow

+3.1% YoY

$1.81BFY 2026

FY23 $693.3MFY24 $1.40BFY25 $1.75BFY26 $1.81B

Free Cash Flow

-0.7% YoY

$1.65BFY 2026

FY23 $573.6MFY24 $1.30BFY25 $1.66BFY26 $1.65B

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$5.65B +9.9%	$5.15B +9.8%	$4.69B +10.9%	$4.22B +18.0%	$3.58B +11.9%	$3.20B
Net Income	$1.52B +8.8%	$1.40B +37.2%	$1.02B +13.7%	$897.6M +15.2%	$779.4M +64.3%	$474.5M
Operating Income	$1.89B +11.9%	$1.69B +27.7%	$1.32B +16.6%	$1.13B +13.2%	$1.00B +10.7%	$903.7M
EPS (Diluted)	$10.43 +9.7%	$9.51 +37.4%	$6.92 +13.6%	$6.09 +14.9%	$5.30 +63.6%	$3.24
Total Assets	$8.97B +9.7%	$8.17B +18.9%	$6.87B +1.8%	$6.75B +32.5%	$5.10B +7.8%	$4.73B
Total Debt	$659.4M -1.3%	$668.3M -5.5%	$707.2M -50.9%	$1.44B +85.9%	$775.2M +18.3%	$655.4M
Operating Cash Flow	$1.81B +3.1%	$1.75B +25.0%	$1.40B +102.1%	$693.3M +97.4%	$351.1M -52.3%	$736.7M
Free Cash Flow	$1.65B -0.7%	$1.66B +27.6%	$1.30B +126.9%	$573.6M +165.2%	$216.3M -65.9%	$634.0M

Get alerted when RMD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for RESMED INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RMD

BlackRock, Inc.
$2.4B12,317,194 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.8B9,474,129 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.5B7,913,661 sh
STATE STREET CORP
$1.3B6,680,735 sh
GEODE CAPITAL MANAGEMENT, LLC
$845.2M4,352,320 sh
Bank of New York Mellon Corp
$818.0M4,197,610 sh
FIRST TRUST ADVISORS LP
$444.1M2,278,696 sh
Invesco Ltd.
$402.1M2,063,578 sh
MORGAN STANLEY
$375.9M1,928,931 sh
NORTHERN TRUST CORP
$330.6M1,696,674 sh

Fund	Value	Shares
BlackRock, Inc.	$2.4B	12,317,194
VANGUARD CAPITAL MANAGEMENT LLC	$1.8B	9,474,129
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.5B	7,913,661
STATE STREET CORP	$1.3B	6,680,735
GEODE CAPITAL MANAGEMENT, LLC	$845.2M	4,352,320
Bank of New York Mellon Corp	$818.0M	4,197,610
FIRST TRUST ADVISORS LP	$444.1M	2,278,696
Invesco Ltd.	$402.1M	2,063,578
MORGAN STANLEY	$375.9M	1,928,931
NORTHERN TRUST CORP	$330.6M	1,696,674

Companies Similar to RMD

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

IDXX

IDEXX LABORATORIES INC /DE

AI score

Very similar · 29 shared holders

CAISSE DE DEPOT ET PLACEMENT DU QUEBEC WELCH & FORBES LLC AustralianSuper Pty Ltd

ISRG

INTUITIVE SURGICAL INC

AI score

Very similar · 23 shared holders

Swedbank AB Employees Provident Fund Board WORLDQUANT MILLENNIUM ADVISORS LLC

INCY

INCYTE CORP

AI score

Very similar · 37 shared holders

CAISSE DE DEPOT ET PLACEMENT DU QUEBEC AustralianSuper Pty Ltd WORLDQUANT MILLENNIUM ADVISORS LLC

BSX

BOSTON SCIENTIFIC CORP

AI score

Very similar · 29 shared holders

NORDEA INVESTMENT MANAGEMENT AB Employees Provident Fund Board CAISSE DE DEPOT ET PLACEMENT DU QUEBEC

STE

STERIS plc

AI score

Very similar · 32 shared holders

WORLDQUANT MILLENNIUM ADVISORS LLC VOLORIDGE INVESTMENT MANAGEMENT, LLC Life Cycle Investment Partners Ltd

NBIX

NEUROCRINE BIOSCIENCES INC

AI score

Very similar · 30 shared holders

Swedbank AB CAISSE DE DEPOT ET PLACEMENT DU QUEBEC AustralianSuper Pty Ltd

WST

WEST PHARMACEUTICAL SERVICES INC

AI score

Very similar · 31 shared holders

National Pension Service Vest Financial, LLC AVIVA PLC

VRTX

VERTEX PHARMACEUTICALS INC / MA

AI score

Very similar · 33 shared holders

Swedbank AB WELCH & FORBES LLC National Pension Service

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RMD on your watchlist

Track score changes the day RESMED INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RMD a good stock to buy?

13F Pro's AI-powered analysis of RESMED INC (RMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RMD are available on the RMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RMD is classified as a large company.

Which hedge funds own RMD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of RESMED INC's investment landscape.